Views
4 years ago

C1 - GD Elikir - 3/2017

  • Text
  • Elikir
  • Hdl
  • Cetp
  • Colesterol
  • Posprandial
  • Intestinal
  • Cardio
  • Libro
  • Cardiovascular
  • Diferentes
  • Fibratos
  • Remanentes
  • Receptor
  • Apob
  • Vldl
  • Metabolismo
  • Niveles
  • Colesterol
Metabolismo de las lipoproteínas plasmáticas

EM Ylarri //

EM Ylarri // Farmacología cardiovascular. De la molécula al paciente. Dislipemias y aterogénesis • Libby P and Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers. Circ Res 2015;116(2):307-311. • Lipinski MJ, Benedetto U, Escarcega RO. The impact of proprotein convertase subtilisinkexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eu Heart J 2015. • Lorenzatti AJ and Retzlaff BM. Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?. International J Cardiol 2016;221:581– 586. doi.org/10.1016/j.ijcard.2016.07.061. • Lozada AF, Elikir GD. Dislipemias genéticas. Programa de actualización continua de la Sociedad Argentina de Cardiología (ProSAC) 2014. Disponible en www.sac.org.ar • Nicholls SJ, Lincoff A, Barter P, et al. Late-Breaking Clinical Trials II. The ACCELERATE trial: impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular outcome. Presentado en 65th Annual Scientific Session of the American College of Cardiology, abril 2-4, 2016; Chicago, IL. • Nordestgaard B, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-635. • Nordestgaard B, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 2010;31:2844–2853. • Olofsson SO, Wiklund O, and Borén J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vascular Health and Risk Management 2007;3(4):491-502. • Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evidence 2012;7:29-38. • Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYS- SEY outcomes trial. Am Heart J 2014;168:682-689. • The Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-2506. • Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380(9841):572-580. • Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case- control study. Lancet. 2004;364(9438):937-952. 26

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015